{"schema_version":"secwatch.filing_event.v1","accession":"0001564590-21-047679","form_type":"8-K","ticker":"ATYR","cik":"0001339970","company_name":"aTYR PHARMA INC","filed_at":"2021-09-13T23:59:59+00:00","discovered_at":"2026-05-14T18:04:17.763403+00:00","generated_at":"2026-06-29T04:06:47.005331+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"confidence":"high","headline":"aTyr Pharma Announces Positive Phase 1b/2a Results for ATYR1923 in Pulmonary Sarcoidosis","bullets":["ATYR1923 safe and well-tolerated with no drug-related serious adverse events in 37-patient pulmonary sarcoidosis trial.","5.0 mg/kg group achieved 58% steroid reduction from baseline and 33% of patients tapered completely off steroids.","Absolute improvement in forced vital capacity (FVC) of 3.3% at week 24 in 5.0 mg/kg group vs placebo.","Clinically meaningful improvements in dyspnea, cough, fatigue and King's Sarcoidosis scores in 5.0 mg/kg group.","Company plans FDA end-of-Phase 2 meeting and expects to initiate registrational trial in 2022."],"urls":{"canonical":"https://secwatch.observer/filing/0001564590-21-047679","json":"https://secwatch.observer/filing/0001564590-21-047679.json","markdown":"https://secwatch.observer/filing/0001564590-21-047679.md","text":"https://secwatch.observer/filing/0001564590-21-047679.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1339970/000156459021047679/0001564590-21-047679-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1339970/000156459021047679/life-8k_20210913.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-29T04:06:47.005331+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}